Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities and Leica Biosystems, a global leader in workflow solutions and automation, have announced the European launch of the CE-IVD marked RNAscope™ In Situ Hybridization Detection Kit for automation on the BOND-III platform. The combination of Bio-Techne's RNAscope and Leica's BOND-III promises to provide pathologists access to an unprecedented number of leading applications to support their diagnostics labs.
Tissue-based diagnostics are growing in globally and there is a demand for high throughput, streamlined workflows that enable visualization of genomic expression at the individual cell level. RNAscope, a leading RNA ISH technology, improves on traditional ISH methodologies through higher target sensitivity and specificity. This combined with the automation of the Leica BOND-III, will optimize and streamline the applications in diagnostic labs.
"We are excited to expand our Leica partnership with the launch of our CE-IVD marked detection kit in Europe. Diagnostic labs will now have access to the fully automated RNAscope technology, providing pathologists with a powerful new tool to evaluate biomarkers involved in cancer, infection, and other important human diseases," said Kim Kelderman, President, Diagnostics and Genomics Segment of Bio-Techne.
"During these difficult times and ever-changing world due to COVID-19, we are excited about this innovative product as it delivers the benefit of improved workflow, reduced hands-on time and provides our European pathology partners an additional tool in their IVD tool box against various diseases," said Colin White, Global Vice President, Advanced Staining and Imaging at Leica Biosystems.
The RNAscope In Situ Hybridization Detection Kit and Probes are a robust technology that identifies RNA expression patterns and localization at the single-cell level with spatial and morphologic context. The RNAscope technology is highly sensitive, and specific due to its double Z probe design, resulting in an extremely high signal-to-noise ratio of staining in various tissues types, allowing diagnostic pathologists to visualize, localize, and quantify biomarker expression simultaneously.
Building on its legacy of excellence in advanced staining technology and pathology processes the new BOND-III makes it easier for labs to quickly and consistently deliver complete cases to pathologists. With optimal patient care depending on an accurate and timely diagnosis, the latest advance to the BOND-III stainer incorporates a unique set of productivity innovations to support pathology labs' drive for procedural efficiency and diagnostic confidence.
Want more of the latest science news straight to your inbox? Become a member of SelectScience for free today>>